According to data from RNC Pharma, in the first six months of 2025, retail sales of veterinary drugs—including online channels—reached 137.2 million minimum marketed doses (MMD), up 13.5% year-over-year. In monetary terms, the market grew by 14.5%, totaling 25.4 billion rubles. The share of domestic companies in retail veterinary medicine sales exceeded 53%, reflecting steady growth in local production.
The online segment was the primary driver of growth, with analysts reporting a 55% increase in rubles and a 45% rise in physical units. Traditional retail points saw modest gains of 3% in monetary value and 7% in natural units.
Despite the rise of Russian producers, the top position in market share remains with American firm Zoetis, which holds 13.2%. Its sales increased by 16% in rubles and 12% in MMD. Symparica, an ectoparasitic drug, remains the company’s key product, accounting for over 73% of its retail revenue.
The Russian company Ecoprom ranks second with a 10.7% market share, climbing in 2024 due to increased sales of its Inspector and Rolfclub 3D antiparasitic product lines. Slovenian pharmaceutical company KRKA occupies third place with 9.1%, driven by a 32% sales increase for its Milprazone drug.
The top 10 includes five Russian companies, collectively holding more than 35% of the market by value. Among them, Agrovetzashchita stands out for its extensive product range (88 brands) and leads in physical sales, accounting for 18% of the market in units.
Earlier, RNC Pharma reported that prices for veterinary drugs in the Russian retail market, including online sales, increased by 17.7% in the first quarter of 2025 compared to the same period last year. In March of this year, the rise in prices for domestic medicines for animals outpaced the increase for imported products.